Call Us: 1.800.873.5297


FDA concerns over Chantix, an anti-smoking drug, continue

Chantix was among the 20 medications under investigation for potential safety issues, according to an updated list from the Food and Drug Administration released on June 4, 2009.

Chantix, a twice daily pill, eases nicotine withdrawal symptoms by blocking the pleasurable effects of nicotine. Chantix is manufactured by Pfizer of New York. Approved in May 2006, Chantix quickly became one of the fastest growing products on Pfizer’s balance sheet, though sales fell 4 percent in 2008 to $846 million.

The FDA is investigating reports of injury, visual impairment and other problems connected with Chantix, which is designed to help smokers quit. In 2008, the FDA warned that Chantix may be linked to psychiatric problems, including suicidal behavior and vivid dreams.

Regulators first began investigating Chantix in 2007 after receiving several reports of psychiatric problems, including suicidal thoughts. That prompted Pfizer to update the drug’s labeling that patients should be monitored for unusual behavior.

Institute for Save Medical Practices, a nonprofit group, highlighted 1,001 reports to the FDA of serious injuries linked to the drug over a three-month period, more than for the 10 best-selling brand name drugs combined.

ISMP found 15 cases of Chantix patients involved in traffic accidents, and 52 additional cases involving blackouts or loss of consciousness. The FDA said it taking a second look at the Chantix warnings.

Pfizer said at the time that the high number of reports might be linked to greater publicity about the side effects. It also contends that the drug’s benefits clearly outweigh its risks. “We stand by the efficacy and safety profile of Chantix,” the company said in a statement. “There are few things that provide greater health benefits than quitting smoking. Pfizer is committed to reducing the prevalence of smoking globally. As part of that mission, we want to increase peoples’ understanding of the dangers of smoking and the benefits of quitting.”

The Federal Aviation Administration has banned use of Chantix by pilots and air traffic controllers.

While the current label cautions that patients should not drive or operate heavy machinery, this language is standard for many medications.

Reports of adverse events associated with Chantix should be reported to the FDA.

The FDA can be contacted via:
Online at
Phone at 1-800-FDA-1088
Fax at 1-800-FDA-0178, using the MedWatch Form 3500
(available at getforms.htm)
Mail, using the postage-paid MedWatch Form 3500 (see above), to MedWatch, 5600
Fishers Lane, Rockville, MD 20852-9787

For more information please see:

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.